Fostamatinib is a highly selective Syk inhibitor, and it was proven to improve MPO-ANCA glomerulonephritis in a pre-clinical ANCA vasculitis model in Wistar Kyoto rats (158). The gene discussed is SYK; the disease is glomerulonephritis.